Wealth Enhancement Advisory Services LLC Invests $213,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

Wealth Enhancement Advisory Services LLC bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 8,818 shares of the company’s stock, valued at approximately $213,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. IronOak Wealth LLC. acquired a new stake in Hims & Hers Health during the fourth quarter worth approximately $922,000. Kilter Group LLC acquired a new stake in Hims & Hers Health in the fourth quarter valued at approximately $1,053,000. Cim LLC raised its stake in shares of Hims & Hers Health by 1.0% during the fourth quarter. Cim LLC now owns 71,869 shares of the company’s stock valued at $1,738,000 after acquiring an additional 694 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in shares of Hims & Hers Health during the fourth quarter valued at $4,900,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in Hims & Hers Health during the fourth quarter worth $200,000. 63.52% of the stock is owned by institutional investors.

Insider Activity

In other Hims & Hers Health news, COO Melissa Baird sold 67,687 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $34.84, for a total transaction of $2,358,215.08. Following the completion of the transaction, the chief operating officer now owns 751,243 shares of the company’s stock, valued at approximately $26,173,306.12. This trade represents a 8.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 36,460 shares of the stock in a transaction that occurred on Wednesday, April 16th. The shares were sold at an average price of $28.04, for a total transaction of $1,022,338.40. Following the sale, the chief executive officer now owns 92,103 shares in the company, valued at approximately $2,582,568.12. The trade was a 28.36% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 476,653 shares of company stock valued at $20,679,956. Insiders own 13.71% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $59.86 on Tuesday. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98. The firm has a fifty day moving average of $45.77 and a 200 day moving average of $38.46. The firm has a market capitalization of $13.40 billion, a PE ratio of 136.04 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s revenue for the quarter was up 110.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.05 earnings per share. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on HIMS shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Bank of America boosted their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an “underperform” rating in a report on Tuesday, April 29th. Truist Financial dropped their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research note on Thursday, April 10th. TD Cowen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating and lowered their price target for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Finally, UBS Group reissued a “mixed” rating on shares of Hims & Hers Health in a report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $38.00.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.